Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Demant ASWILYY 96 3-Year EBITDA Growth Rate is 8.80% as of Dec. 2025, which is 28% below its 10-year median of 12.20. GuruFocus rates WILYY with a GF Score™ of 96/100 and a GF Value™ of $23.73 (Fairly Valued). The stock has 7 warning signs investors should review. Among 692 Medical Devices & Instruments companies, Demant AS ranks better than 50.43% on this metric.
During the past 12 months, Demant AS's average EBITDA Per Share Growth Rate was -8.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 8.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 16.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 13.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Demant AS was 33.80% per year. The lowest was -4.90% per year. And the median was 12.20% per year.
Demant AS (OTCPK:WILYY) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Demant AS 3-Year EBITDA Growth Rate Related Terms
WILYY vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Demant AS's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Demant AS 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Demant AS's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Demant AS's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 8.80% mean?
Demant AS (WILYY) has a 3-Year EBITDA Growth Rate of 8.80% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Demant AS and its competitors. This is 28% below median its historical median of 12.20. According to the industry distribution chart, Demant AS ranks #343 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 49.6%.
Is Demant AS's 3-Year EBITDA Growth Rate too high?
Demant AS's current 3-Year EBITDA Growth Rate of 8.80% is 28% below median its 10-year median of 12.20. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. Demant AS's value of 8.80% is 7.3% above this industry median. Based on the distribution chart, Demant AS ranks #343 out of 692 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Demant AS has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Demant AS's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Demant AS ranks #343 out of 692 companies for 3-Year EBITDA Growth Rate. This puts Demant AS in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. Demant AS's value of 8.80% is 7.3% above this benchmark. While the company's 10-year median is 12.20 vs. the industry median of 8.20, Demant AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Demant AS's current 3-Year EBITDA Growth Rate of 8.80% is 7.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Demant AS and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Demant AS's current 3-Year EBITDA Growth Rate is 8.80%, which is 28% below median its own 10-year median of 12.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Demant AS stock overvalued right now?
Based on GuruFocus' analysis, Demant AS (WILYY) is currently considered Fairly Valued. The stock's GF Value™ is $23.73, compared to a current price of $21.87 — trading 7.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 8.80%, which is 28% below median its 10-year median of 12.20 and 7.3% above the Medical Devices & Instruments industry median of 8.20. Demant AS's overall GF Score™ is 96/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Demant AS (WILYY), the current 3-Year EBITDA Growth Rate is 8.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Demant AS (WILYY) Overvalued in 2026?
Based on GuruFocus' analysis, Demant AS stock appears to be undervalued.
The current stock price of $21.87 is trading 7.8% below its estimated GF Value™ of $23.73.
GuruFocus considers Demant AS to be Fairly Valued.
Key valuation signals for WILYY:
3-Year EBITDA Growth Rate: 8.80% (28% below median its 10-year median of 12.20)
GF Value™: $23.73 vs. price of $21.87 (7.8% below fair value)
Industry Position: 7.3% above the Medical Devices & Instruments median (#343 of 692)
No single metric tells the full story. See the WILYY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Demant is a Denmark-based manufacturer and distributor of hearing solutions, such as hearing aid devices and diagnostic equipment. More than 80% of the company's sales come from North America and Europe.
96GF Score
Get the complete analysis for WILYY
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WILYY has been successfully added to your 
